Abzena plc (AIM: ABZA)

https://www.abzena.com

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits. Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture. PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups. Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA. *

	Start	2014-07-10 renamed
	Group	Abzena (Group)
	Today	Abzena Ltd. (since 2018)
	Predecessor	Abzena Ltd. (OLD)
	Successor	Abzena Ltd. (since 2018)
	Industry	biopharmaceutical
	Industry 2	drug development
	Person	Burt, John (Abzena 201405– CEO before Antitope + PolyTherics + Thiakis)
	Person 2	Smith, Julian (PolyTherics 201309– CFO before Imperial Innovations + RadioScape)

	Region	London, Greater London
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2022-02-01

Basic data	Employees	D: 101 to 500 (2018-03-30)
	Currency	GBP
	Annual sales	21,950,000 (revenues, consolidated (2017/18) 2018-03-31)
	Profit	-14,161,000 (2018-03-31)
	Cash	6,785,000 (2013-03-31)

		* Document for »About Section«:

		Record changed: 2023-07-10